<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Although newer <z:chebi fb="1" ids="35705">immunosuppressive agents</z:chebi>, such as mTOR (mammalian target of <z:chebi fb="0" ids="9168">rapamycin</z:chebi>) inhibitors, have lowered the occurrence of <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> after transplantation, <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> is still a leading cause of <z:hpo ids='HP_0011420'>death</z:hpo> late after heart transplantation </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="35664">Statins</z:chebi> may have an impact on clinical outcomes beyond their <z:chebi fb="23" ids="18059">lipid</z:chebi>-lowering effects </plain></SENT>
<SENT sid="2" pm="."><plain>The aim of the present study was to delineate whether <z:chebi fb="0" ids="35664">statin</z:chebi> therapy has an impact on <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risk and total mortality after heart transplantation </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS AND RESULTS: A total of 255 patients who underwent heart transplantation at the University Hospital Zurich between 1985 and 2007 and survived the first year were included in the present study </plain></SENT>
<SENT sid="4" pm="."><plain>The primary outcome measure was the occurrence of any <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e>; the secondary end point was overall survival </plain></SENT>
<SENT sid="5" pm="."><plain>During follow-up, a <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> was diagnosed in 108 patients (42%) </plain></SENT>
<SENT sid="6" pm="."><plain>The cumulative incidence of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> 8 years after transplantation was reduced in patients receiving a <z:chebi fb="0" ids="35664">statin</z:chebi> (34% versus 13%; 95% confidence interval, 0.25-0.43 versus 0.07-0.18; P&lt;0.003) </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="35664">Statin</z:chebi> use was associated with improved <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-free and overall survival (both P&lt;0.0001) </plain></SENT>
<SENT sid="8" pm="."><plain>A Cox regression model that analyzed the time to <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> formation with or without <z:chebi fb="0" ids="35664">statin</z:chebi> therapy, adjusted for age, male sex, type of <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo>, and immunosuppressive therapy (including switch to mTOR inhibitors or tacrolimus), demonstrated a superior survival in the <z:chebi fb="0" ids="35664">statin</z:chebi> group </plain></SENT>
<SENT sid="9" pm="."><plain><z:chebi fb="0" ids="35664">Statins</z:chebi> reduced the hazard of occurrence of any <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> by 67% (hazard ratio, 0.33; 95% confidence interval, 0.21-0.51; P&lt;0.0001) </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: Although it is not possible to adjust for <z:hpo ids='HP_0000001'>all</z:hpo> potential confounders because of the very long follow-up period, this registry suggests that <z:chebi fb="0" ids="35664">statin</z:chebi> use is associated with improved <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-free and overall survival after cardiac transplantation </plain></SENT>
<SENT sid="11" pm="."><plain>These data will need to be confirmed in a prospective trial </plain></SENT>
</text></document>